IE41628L - Erythromycin pyroglutamate - Google Patents

Erythromycin pyroglutamate

Info

Publication number
IE41628L
IE41628L IE147275A IE147275A IE41628L IE 41628 L IE41628 L IE 41628L IE 147275 A IE147275 A IE 147275A IE 147275 A IE147275 A IE 147275A IE 41628 L IE41628 L IE 41628L
Authority
IE
Ireland
Prior art keywords
erythromycin
pyroglutamate
july
gb1485210a
perlingually
Prior art date
Application number
IE147275A
Other versions
IE41628B1 (en
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of IE41628L publication Critical patent/IE41628L/en
Publication of IE41628B1 publication Critical patent/IE41628B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1485210 Compositions containing erythromycin pyroglutamate ROUSSEL-UCLAF 2 July 1975 [2 July 1974] 27809/75 Heading A5B [Also in Division C2] Pharmaceutical compositions having bacteriostatic and bactericidal activity comprise, as active ingredient, erythromycin pyroglutamate, in association with a suitable pharmaceutical vehicle and optionally other active ingredients such as erythromycin base and a colistin salt, e.g. the sulphate. They may be administered orally, perlingually, topically or transcutaneously in the form of tablets, capsules, injectable solutions or suspensions, creams or ointments. [GB1485210A]
IE147275A 1974-07-02 1975-07-02 New erythromycin salt process for preparing it and compositions incorporating it IE41628B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7423013A FR2302084A1 (en) 1974-07-02 1974-07-02 NEW ERYTHROMYCIN SALT, ITS PREPARATION PROCESS AND ITS APPLICATION AS A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
IE41628L true IE41628L (en) 1976-01-02
IE41628B1 IE41628B1 (en) 1980-02-13

Family

ID=9140790

Family Applications (1)

Application Number Title Priority Date Filing Date
IE147275A IE41628B1 (en) 1974-07-02 1975-07-02 New erythromycin salt process for preparing it and compositions incorporating it

Country Status (11)

Country Link
JP (1) JPS5129217A (en)
BE (1) BE830842A (en)
CA (1) CA1025442A (en)
CH (1) CH599152A5 (en)
DE (1) DE2529538A1 (en)
DK (1) DK299375A (en)
FR (1) FR2302084A1 (en)
GB (1) GB1485210A (en)
IE (1) IE41628B1 (en)
LU (1) LU72866A1 (en)
NL (1) NL7507863A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5633353A (en) * 1979-08-20 1981-04-03 Toray Ind Inc Reeling-out method for thread
DK0804088T3 (en) * 1994-06-29 2000-11-20 Meiji Seika Kaisha Stabilized composition comprising solisine sulphate

Also Published As

Publication number Publication date
JPS5129217A (en) 1976-03-12
DK299375A (en) 1976-01-03
LU72866A1 (en) 1976-04-13
BE830842A (en) 1975-12-30
CA1025442A (en) 1978-01-31
FR2302084B1 (en) 1979-05-18
GB1485210A (en) 1977-09-08
CH599152A5 (en) 1978-05-12
FR2302084A1 (en) 1976-09-24
IE41628B1 (en) 1980-02-13
NL7507863A (en) 1976-01-06
DE2529538A1 (en) 1976-01-22

Similar Documents

Publication Publication Date Title
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
CA2021116A1 (en) Topical compositions containing live yeast cell derivative and other topically active medicinal ingredients
EP0208519A3 (en) Solubilized composition of hardly-soluble pharmaceutical product
GB1458251A (en) 1-phenyl-2-amino-ethanol derivatives
IE41628L (en) Erythromycin pyroglutamate
GB1352257A (en) Pyridyltriazoles their preparation and compositions containing them
GB1425150A (en) Therapeutically active phenoxyalkylamines
IL45795A (en) 2,2-dialkyl-3-spirocycloalkane-cyclopropane carboxylic acid esters their preparation and pesticidal compositions containing them
GB1252286A (en)
CA984849A (en) Metal complexes of n,n'-dialkylesters of ethylenedinitrilotetraacetic acid and compositions stabilized thereby
IE35507L (en) Preparations containing tetrahydrocarbazole¹derivatives
GB1275607A (en) Pharmaceutical compositions
IE34386B1 (en) Pharmaceutical compositions
IE39587B1 (en) Antibacterial compositions
GB1451389A (en) Indolobenzazepines
CA1026678A (en) Solubilized acetylsalicylic acid composition
IE38940B1 (en) Pharmaceutical compositions containing p-chlorohippuric acid or salts thereof
IE35047L (en) Benzazepine derivatives.
GB1397675A (en) Proline compounds
IE37288L (en) Crane assembly
GB1193438A (en) Barbituric Acid Derivatives, preparation thereof and Pharmaceutical Compositions containing them
GB1264197A (en)
AU476756B2 (en) PHARMACOLOGICALLY ACTIVE 4, 8-DIMETHOXY-FURO-(3',2'-F) BENZOXAZOL-2-yl ACETHYDROXAMIC ACID
GB1265114A (en)
IE34501L (en) Sulphonyl-imidazolidines